^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TmMSTN-01
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gilead, University of Pennsylvania
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Related drugs:
Phase 1
University of Pennsylvania
Active, not recruiting
Last update posted :
01/24/2024
Initiation :
04/06/2017
Primary completion :
03/01/2025
Completion :
03/01/2025
PD-L1
|
MSLN expression
|
cyclophosphamide • fludarabine IV • TmMSTN-01
Share
